Estimation of the Orexin Receptor Occupancy From Human Plasma Pharmacokinetics of Vornorexant, a Novel Dual Orexin 1/2 Receptor Antagonist for the Treatment of Insomnia
Pharmacology Research & Perspectives · 2026
DOI: 10.1002/prp2.70217 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, 2026. Verfasst von Shunsuke Kamigaso und 10 weiteren Autor:innen. Beteiligte Einrichtung: Research Center, Taisho Pharmaceutical Co., Ltd., Saitama, Japan. Hauptthemen laut MEDLINE: Orexin Receptor Antagonists, Orexin Receptors, Sleep Initiation and Maintenance Disorders, Triazoles. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Taisho Pharmaceutical, Taisho Toyama Pharmaceutical Company.
Themen: Schlaf
Abstract (Originalsprache)
Vornorexant is a novel dual orexin receptor antagonist (DORA) for the treatment of insomnia with a short elimination half‐life. Estimation of the human orexin receptor occupancy can provide insight into the duration of the sleep‐promoting effect of DORAs. Herein, we developed a pharmacokinetic‐receptor occupancy (PK/RO) model for OX 1 and OX 2 receptors in rats and estimated their receptor occupancy in humans based on the human plasma concentrations after oral administration of vornorexant. The estimated occupancy of the human OX 2 receptor, which is primarily involved in sleep induction, exceeded 70% at 30 min after dosing of therapeutic doses of 5 and 10 mg. The human OX 2 receptor occupancy at 6 h post‐dose of 5 and 10 mg was estimated to be approximately 50% and 60%, respectively, comparable to the occupancy necessary to exert sleep‐promoting effects in rats. Occupancy of the human OX 1 receptor by vornorexant was higher than that of the OX 2 receptor. The estimated human OX 1 and OX 2 receptor occupancy decreased with short half‐lives depending on the plasma concentration. These results suggest that vornorexant exerts rapid sleep‐promoting effects and maintains sleep for at least 6 h, and these estimations of the OX 2 receptor occupancy could support the clinical results. Vornorexant may have a favorable PK/RO profile for rapid sleep onset and sufficient sleep maintenance with minimal next‐day residual effects in humans.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Center, Taisho Pharmaceutical Co., Ltd., Saitama, Japan.
- Development Headquarters, Taisho Pharmaceutical Co., Ltd., Toshima, Japan.
ORCID-Profile: Yoshihiro Konno, Daiji Kambe
Förderung
- Taisho Pharmaceutical
- Taisho Toyama Pharmaceutical Company
Zitieren
APA
Kamigaso, S., Konno, Y., Hikichi, H., Kambe, D., Mano, Y., Tokumaru, Y., Mori, H., Yamasaki, H., Chino, Y., Hachiuma, K., & Mizuno-Yasuhira, A. (2026). Estimation of the Orexin Receptor Occupancy From Human Plasma Pharmacokinetics of Vornorexant, a Novel Dual Orexin 1/2 Receptor Antagonist for the Treatment of Insomnia. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.70217
Vancouver
Kamigaso S, Konno Y, Hikichi H, Kambe D, Mano Y, Tokumaru Y, et al. Estimation of the Orexin Receptor Occupancy From Human Plasma Pharmacokinetics of Vornorexant, a Novel Dual Orexin 1/2 Receptor Antagonist for the Treatment of Insomnia. Pharmacology Research & Perspectives. 2026. doi:10.1002/prp2.70217
BibTeX
@article{Kamigaso2026,
author = {Kamigaso, Shunsuke and Konno, Yoshihiro and Hikichi, Hirohiko and Kambe, Daiji and Mano, Yoko and Tokumaru, Yuichi and Mori, Haruyuki and Yamasaki, Hironori and Chino, Yukihiro and Hachiuma, Kenji and Mizuno-Yasuhira, Akiko},
title = {Estimation of the Orexin Receptor Occupancy From Human Plasma Pharmacokinetics of Vornorexant, a Novel Dual Orexin 1/2 Receptor Antagonist for the Treatment of Insomnia},
journal = {Pharmacology Research & Perspectives},
year = {2026},
doi = {10.1002/prp2.70217}
}
EUVIMED